School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Medicine (Baltimore). 2020 Dec 24;99(52):e23912. doi: 10.1097/MD.0000000000023912.
Asthma is one of the most common chronic diseases in the world, with ∼100 million asthma patients worldwide. China has become one of the countries with the highest asthma death rate in the world. Asthma is a chronic airway inflammatory disease. Patients with this disease may have symptoms such as cough, wheezing, and difficulty breathing. For many years, Western medicine has mainly used anti-inflammatory, anti-bronchial spasm, asthma, cough, and oxygen to treat this disease, but the effect is not good. Tuina is a common treatment for asthma in China. But at present, there is no systematic evaluation report on its therapeutic effectiveness and safety. This protocol aims to reveal the efficacy and safety of Tuina for treating asthma.
The following databases will be searched by electronic methods: PubMed, EBASE, WHO International Clinical Trials Registry Platform, Embase, the Chinese Biomedical Literature Database (CBM), Wan-fang Data (WANFANG), the China National Knowledge Infrastructure (CNKI), and other sources from inception to November 2020. Bias risk, subgroup analysis, data synthesis, and meta-analyses will be assessed with RevMan V.5.3 software if the data is met inclusion conditions.
This study will present a quality evidence of Tuina for the treatment of astma patients.
The systematic review will present reliable evidence to judge whether or not Tuina is a safe and effective intervention for asthma patients. International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) registration number: INPLASY2020110100.
哮喘是世界上最常见的慢性疾病之一，全球约有 1 亿名哮喘患者。中国已成为世界上哮喘死亡率最高的国家之一。哮喘是一种慢性气道炎症性疾病，患者可能会出现咳嗽、喘息和呼吸困难等症状。多年来，西医主要采用抗炎、抗支气管痉挛、平喘、镇咳、吸氧等方法治疗该病，但效果不佳。推拿是中国治疗哮喘的常用方法。但目前，尚无系统评价报告其疗效和安全性。本方案旨在揭示推拿治疗哮喘的疗效和安全性。
将通过电子方式检索以下数据库：PubMed、EBASE、世界卫生组织国际临床试验注册平台、Embase、中国生物医学文献数据库（CBM）、万方数据（WANFANG）、中国国家知识基础设施（CNKI）和其他来源，从建库起至 2020 年 11 月。如果数据符合纳入条件，将使用 RevMan V.5.3 软件评估偏倚风险、亚组分析、数据综合和荟萃分析。
本研究将提供推拿治疗哮喘患者的高质量证据。
系统评价将提供可靠的证据，以判断推拿是否是哮喘患者安全有效的干预措施。国际注册系统评价和荟萃分析方案平台（INPLASY）注册号：INPLASY2020110100。
